Logo

GMED

Globus Medical, Inc.

GMED

Globus Medical, Inc. • NYSE
$91.04 ▼ -0.04% (-0.04)
Market Cap $12.18 B
52w High $94.93
52w Low $51.79
Dividend Yield 0%
P/E 29.46
Volume 567.22K
Outstanding Shares 133.83M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $769.048M ▲ $351.664M ▼ $118.966M ▼ 15.469% ▼ $0.88 ▼ $215.12M ▲
Q2-2025 $745.342M ▲ $420.468M ▲ $202.846M ▲ 27.215% ▲ $1.5 ▲ $193.443M ▲
Q1-2025 $598.121M ▼ $305.72M ▼ $75.462M ▲ 12.617% ▲ $0.55 ▲ $164.135M ▲
Q4-2024 $657.293M ▲ $333.582M ▲ $26.505M ▼ 4.032% ▼ $0.19 ▼ $145.283M ▲
Q3-2024 $625.705M $307.092M $51.836M 8.284% $0.38 $115.943M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $390.523M ▲ $5.096B ▲ $696.815M ▲ $4.399B ▲
Q2-2025 $229.446M ▼ $4.961B ▲ $665.406M ▲ $4.296B ▲
Q1-2025 $461.266M ▼ $4.711B ▼ $623.08M ▼ $4.088B ▼
Q4-2024 $890.057M ▲ $5.252B ▲ $1.074B ▲ $4.177B ▲
Q3-2024 $694.706M $5.086B $1.017B $4.069B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $118.966M ▼ $249.695M ▲ $-75.842M ▲ $-32.042M ▼ $142.323M ▲ $218.878M ▲
Q2-2025 $202.846M ▲ $77.865M ▼ $-299.108M ▼ $-24.937M ▲ $-231.82M ▲ $31.303M ▼
Q1-2025 $75.462M ▲ $177.3M ▼ $131.385M ▲ $-635.396M ▼ $-323.172M ▼ $136.197M ▼
Q4-2024 $26.505M ▼ $210.339M ▲ $-104.122M ▼ $59.733M ▲ $161.672M ▼ $193.228M ▲
Q3-2024 $51.836M $203.654M $-14.967M $19.583M $212.342M $161.702M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Emerging Technology
Emerging Technology
 $50.00M ▲$20.00M ▼$40.00M ▲$30.00M ▼
Spine
Spine
 $610.00M ▲$580.00M ▼$710.00M ▲$740.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Globus Medical has grown into a much larger company over the last five years, especially after the NuVasive merger, with revenue rising sharply. However, profit per share has moved the other way: it was stronger a few years ago and has come down more recently. This suggests that while scale has increased, integration costs, higher operating expenses, and some margin pressure are weighing on the bottom line. Gross profitability remains healthy for a medical device company, but the business today is clearly trading some near‑term earnings efficiency for faster growth and a broader portfolio.

Balance Sheet

Balance Sheet The balance sheet shows a company that has bulked up significantly: assets and shareholder equity are now several times larger than they were five years ago, reflecting acquisitions and internal growth. Cash levels have improved meaningfully, giving the firm a solid liquidity cushion. Debt has increased from almost nothing to a modest level, but it still looks manageable relative to the company’s size and equity base. Overall, the financial foundation appears strong, with plenty of equity backing and no obvious signs of balance‑sheet strain, though the company now has more complexity to manage.

Cash Flow

Cash Flow Cash generation is a relative bright spot. Operating cash flow has trended upward over time and remains comfortably positive, and after funding capital spending, the company still produces positive free cash flow. Investment in equipment and facilities has risen, but not to a level that overwhelms cash generation. This pattern suggests that Globus can largely fund its growth and innovation from internal cash, while still having room for strategic moves, provided integration activities and working‑capital needs remain under control.

Competitive Edge

Competitive Edge Globus is now one of the largest spine‑focused device companies globally, with a strong position in robotic‑assisted spine surgery and a broad implant portfolio. The Excelsius ecosystem, combined with products gained from NuVasive and Nevro, gives it a comprehensive offering that can be attractive to hospitals and surgeons looking for integrated solutions. Deep relationships with surgeons, a reputation for innovation, and platform “stickiness” from robotics and software all reinforce its competitive moat. On the other hand, it operates in a fiercely competitive space against much larger diversified players, faces hospital budget constraints, and must prove it can fully realize the benefits of its large acquisitions without losing focus or pricing power.

Innovation and R&D

Innovation and R&D Innovation is at the core of Globus’s strategy. The company has built a leading robotics and navigation platform for spine surgery, is pushing into imaging, software, and potentially augmented‑reality and machine‑learning‑enabled tools, and is extending these capabilities into trauma, joint reconstruction, and pain management. Its rapid design‑to‑prototype cycle and close collaboration with surgeons are important advantages. The flip side is that this strategy demands ongoing, heavy R&D and capital investment, and the company must continually demonstrate that new technologies improve outcomes and justify their cost to hospitals and payers.

Summary

Globus Medical has transformed from a focused spine company into a much larger, more diversified musculoskeletal and pain‑management player, driven by strong revenue growth, major acquisitions, and aggressive innovation in robotics and navigation. Financially, it shows a solid balance sheet and improving cash flows, but near‑term profitability and earnings per share are under pressure as it absorbs acquisitions and invests heavily in its platforms. Its competitive position is strong but contested, with powerful rivals and execution risk around integration and global expansion. The long‑term story centers on whether Globus can turn its technological edge and expanded portfolio into sustained, higher‑margin growth while keeping financial discipline and integration on track.

NEWS

November 6, 2025 · 4:15 PM UTC

Globus Medical Reports Third Quarter 2025 Results

Read more

October 16, 2025 · 4:30 PM UTC

Globus Medical Schedules Third Quarter Earnings Release and Conference Call

Read more

October 14, 2025 · 4:40 PM UTC

Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma

Read more